4DMedical (ASX:4DX) has taken a significant step in the commercial rollout of its flagship CT:VQ technology. It announced that Stanford University has become the first US Academic Medical Centre to adopt the platform under a commercial agreement, less than two months after receiving clearance from the US Food and Drug Administration.
4DMedical secures Stanford as first commercial site and expands AstraZeneca partnership in Brazil
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
PYC to present early polycystic kidney disease trial data at US nephrology conference
October 7, 2026 - - Australian Biotech -
CSL raises US$1.5 billion from US bond investors to refinance debt
October 7, 2026 - - Latest News -
Every serious attempt to reform PBS pricing has run into the same problem
October 7, 2026 - - Latest News -
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 - - Latest News -
The patient who knows what they want is informed and not a danger
October 7, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News
